A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

This study has been completed.
Information provided by:
Cougar Biotechnology, Inc.
ClinicalTrials.gov Identifier:
First received: June 2, 2009
Last updated: February 15, 2011
Last verified: October 2009
This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety & tolerability of noscapine HCl in patients with advanced multiple myeloma

Condition Intervention Phase
Refractory Multiple Myeloma
Drug: Noscapine HCl
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Open Label Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Cougar Biotechnology, Inc.:

Primary Outcome Measures:
  • To determine the maximum tolerated dose [ Time Frame: During the first 28 day treatment cycle ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine the safety and tolerability in the study population [ Time Frame: End of the study treatment ] [ Designated as safety issue: No ]
  • To evaluate the pharmacokinetics of study drug [ Time Frame: End of the study treatment ] [ Designated as safety issue: No ]
  • To assess anti-tumor effects as classified by International Uniform Response Criteria for Multiple Myeloma [ Time Frame: End of the study treatment ] [ Designated as safety issue: No ]

Estimated Enrollment: 32
Study Start Date: November 2007
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: One
Noscapine HCl
Drug: Noscapine HCl
Escalating doses given twice per day
Other Name: Noscapine HCl (CB3304)


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced Multiple Myeloma.
  • Progression after ≥ 2 lines of prior therapy, including at least one steroid, one immunomodulatory agent (iMID), one alkylator, and bortezomib (VELCADE®).
  • ECOG performance status of either 0 or 1.

Exclusion Criteria:

  • Prior chemotherapy with antimicrotubule agents
  • Metastasis involving the brain or spinal cord
  • Clinically significant lung or heart disease
  • Abnormal electrocardiogram

Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00912899

United States, California
Los Angeles, California, United States, 90024
United States, New York
St. Vincent's Comprehensive Cancer Center
New York City, New York, United States, 10011
Weill Medical College of Cornell University
New York City, New York, United States, 10021
Columbia Presbyterian Hospital
New York City, New York, United States, 10032
Sponsors and Collaborators
Cougar Biotechnology, Inc.
  More Information

Additional Information:
Responsible Party: Christopher Haqq, MD PhD / VP Clinical Research and Development, Cougar Biotechnology, Inc.
ClinicalTrials.gov Identifier: NCT00912899     History of Changes
Other Study ID Numbers: COU-NOS-001 
Study First Received: June 2, 2009
Last Updated: February 15, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Cougar Biotechnology, Inc.:
Refractory Multiple Myeloma
Noscapine HCl
Multiple Myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Vascular Diseases
Antitussive Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on May 24, 2016